Home Infusion Therapy Billing 2026

The Three-Way Payer Split Between Drug, Equipment, and Nursing Services Most Practices Miss

By Yagnesh Dave  ·  September 2026  ·  13 min read

Home infusion therapy has a billing structure that genuinely confuses even experienced billers, because one episode of care (say, a patient receiving IV antibiotics at home) actually splits across three distinct benefit categories that don't talk to each other in most billing systems. The drug bills one way, the pump and supplies bill another way as durable medical equipment, and the nursing visit to set up and monitor the infusion bills through a separate home infusion therapy services benefit that Medicare only formally established under the 21st Century Cures Act. Providers who came up billing traditional home health or clinic infusion often bill two of these three pathways correctly and simply never bill the third at all.

This guide covers how the three-way split actually works, the per-diem nursing codes providers most often leave unbilled, and the documentation each pathway requires to hold up under review. This isn't a paperwork detail, it's a revenue line: practices that let this slide are commonly leaving $44,000 to $104,000 a year uncollected.

The Three-Way Split: Drug, Equipment, and Nursing

Understanding home infusion billing starts with recognizing these aren't three optional add-ons to a single bill; they're three separate claims processes, often to different parts of the same payer or even different payers entirely, each with its own coding system and documentation requirements.

The nursing services benefit is the piece most frequently missed entirely, because it's a relatively newer, distinct benefit category that doesn't map cleanly onto either home health billing or standard nursing visit billing; a provider has to specifically bill under the home infusion therapy services G-code set to capture it, and that requires recognizing the visit as belonging to this specific benefit rather than defaulting to a general home health or private-pay nursing visit code.

Eligibility for the home infusion therapy services benefit also depends on the specific drug being infused, CMS maintains a defined list of drugs and drug categories that qualify, tied to whether the drug requires a pump for safe administration and meets the benefit's clinical criteria. A drug that can be safely self-administered by push or gravity infusion without professional supervision generally doesn't qualify for the per-diem nursing benefit even if a nurse happens to be present, which means providers need to check the specific drug against the qualifying list rather than assuming any home-administered infusion automatically qualifies.

The Per-Diem Nursing Codes Providers Underbill

The home infusion therapy services benefit pays a per-diem rate for each day professional nursing services are provided in connection with the infusion, and that per-diem rate is tiered by the complexity of the drug being administered, a straightforward antibiotic infusion pays a different tier than a complex chemotherapy or specialty biologic infusion requiring more intensive monitoring.

Documentation for each per-diem day needs to show the specific nursing activities performed (infusion setup, patient and caregiver education, monitoring for adverse reactions), not just a note confirming "infusion administered as ordered." A generic note that doesn't distinguish what nursing-specific work happened on that visit, separate from the infusion itself, doesn't clearly support billing the professional services component as its own distinct, reimbursable service.

DME Billing: The Pump and Supplies Side

The infusion pump, tubing, and related supplies bill separately through the DME benefit, typically by a DME supplier rather than the clinical provider delivering the nursing care, and that supplier relationship needs its own documentation trail, including a valid physician order specific to the equipment and supplies, updated whenever the treatment plan changes.

Supplier accreditation adds a further layer of DME-specific compliance that home infusion providers sometimes overlook if the DME side of the business is handled by a separate vendor rather than in-house: the DME supplier billing for the pump and supplies has to maintain its own Medicare supplier number and meet DMEPOS supplier standards independently, and a clinical provider that white-labels a DME arrangement without confirming the actual billing supplier's accreditation status is exposed if that supplier turns out not to meet current standards.

Compliance Focus: Coordinating Three Claims Without Duplicating or Dropping Coverage

Federal reviews of home infusion billing have focused on two opposite failure patterns: providers who bill the nursing per-diem and drug components but never capture the DME side (leaving equipment costs unreimbursed, though this is a revenue loss rather than a compliance risk), and providers whose claims across the three pathways don't reconcile, for instance, billing nursing per-diem days that don't correspond to any documented infusion administration on the drug or DME side. That second pattern is the one that draws genuine audit attention, because it suggests services were billed without a clear, coordinated record showing they were actually delivered together as part of the same care episode.

The standard multi-year lookback applied to home health and DME billing reviews generally applies here as well, and the practices that hold up well under review are the ones whose documentation across all three pathways tells the same consistent story (the same dates, the same drug, the same complexity tier) rather than three separate billing systems generating claims that were never actually cross-checked against each other.

Practices that outsource the DME component to a third-party supplier while keeping nursing services in-house face the added challenge of actually getting visibility into what the DME side billed and when, since two separate organizations are each submitting their own claims for the same underlying episode of care. Establishing a simple shared log (dates of service, drug, and supply items dispensed) between the clinical provider and the DME supplier closes this visibility gap and gives both sides what they need to reconcile their claims against a shared, consistent record rather than working from two disconnected systems. That reconciliation habit is what separates a home infusion program that captures its full legitimate reimbursement across all three billing pathways from one that only ever finds out about a gap when a payer's audit letter arrives. Given how many separate touchpoints (pharmacy, DME, and nursing) a single home infusion patient generates in a month, that gap tends to be larger and harder to reconstruct after the fact than in almost any other specialty on this list, which is exactly why the reconciliation habit matters more here than it might in a simpler, single-payer billing scenario.

What Rejected Home Infusion Claims Cost a Pharmacy

Home infusion claims are large and have many moving parts, which makes small gaps expensive. Take a pharmacy with 120 active patients and an average monthly claim of $2,400. If 8% are rejected or delayed because nursing visit documentation doesn't match the pharmacy record, that's about 10 claims and $23,040 of billing in limbo every month.

Most of that money does come back, but late. At a 45-day delay the pharmacy is financing the drug, the supplies and the nursing visits for an extra month and a half, which is the real cost of a documentation gap.

The Cash Flow Cost of Slow Home Infusion Billing

Think about the timing. If the pharmacy bills $288,000 a month and the average claim takes 20 days longer than it should to go out, about $192,000 is sitting unbilled at any moment. That's cash the pharmacy needs for drug purchases and nursing payroll.

A weekly claims checkpoint helps. List every dispensed order from the past 7 days that hasn't been billed, and assign a name to each one. Cutting the lag by even 10 days frees roughly $96,000 of working capital in this example.

Frequently Asked Questions About Home Infusion Therapy Billing 2026

Why does home infusion therapy bill through three separate payer pathways?

One home infusion episode involves three distinct components that Medicare and most payers treat as separate benefit categories: the drug itself (billed through the Part B drug benefit or pharmacy benefit), the pump and supplies (billed through the durable medical equipment benefit, typically by a DME supplier), and the nursing visit for setup and monitoring (billed through the home infusion therapy services benefit using per-diem G-codes). Providers accustomed to simpler billing structures often bill only two of the three and miss legitimate revenue on the third.

What is the home infusion therapy services per-diem benefit?

It's a Medicare benefit, established under the 21st Century Cures Act, that pays a per-diem rate for professional nursing services provided in connection with a home infusion, tiered by the complexity of the drug being administered. It's billed separately from both the drug itself and the DME supplies, using its own G-code set, and is one of the most commonly missed billing components in home infusion care.

What documentation does DME billing for a home infusion pump require?

DME billing requires a valid, treatment-specific physician order for the pump and supplies, which needs to be updated whenever the treatment plan changes, a new drug, a different infusion duration, or different supply needs. Continuing to bill under an outdated order that no longer matches the current treatment plan is one of the most common findings in home infusion DME audits.